163 related articles for article (PubMed ID: 17350670)
21. Microinvasive (T1mic) lobular carcinoma of the breast: clinicopathologic profile of 16 cases.
Ross DS; Hoda SA
Am J Surg Pathol; 2011 May; 35(5):750-6. PubMed ID: 21415700
[TBL] [Abstract][Full Text] [Related]
22. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
23. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of immunocytochemical detection of tumor markers (XIAP, phosphohistone H1 and p63) in FNA cellblock samples from head and neck squamous cell carcinoma.
Wu M; Kafanas A; Gan L; Kohtz DS; Zhang L; Genden E; Burstein DE
Diagn Cytopathol; 2008 Nov; 36(11):797-800. PubMed ID: 18831009
[TBL] [Abstract][Full Text] [Related]
25. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
26. E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma.
Wahed A; Connelly J; Reese T
Ann Diagn Pathol; 2002 Dec; 6(6):349-51. PubMed ID: 12478484
[TBL] [Abstract][Full Text] [Related]
27. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
28. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma.
Gamallo C; Palacios J; Suarez A; Pizarro A; Navarro P; Quintanilla M; Cano A
Am J Pathol; 1993 Apr; 142(4):987-93. PubMed ID: 7682767
[TBL] [Abstract][Full Text] [Related]
29. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
30. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast?
Erkus M; Meteoglu I; Culhaci N; Meydan N; Erdogdu I
Saudi Med J; 2006 Sep; 27(9):1329-33. PubMed ID: 16951768
[TBL] [Abstract][Full Text] [Related]
31. [Expression and prognostic value of transcriptional factor sp1 in breast cancer].
Wang XB; Peng WQ; Yi ZJ; Zhu SL; Gan QH
Ai Zheng; 2007 Sep; 26(9):996-1000. PubMed ID: 17927860
[TBL] [Abstract][Full Text] [Related]
32. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
Zhang R; Zhang H; Wei H; Luo X
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
[TBL] [Abstract][Full Text] [Related]
33. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
34. BigH3 protein expression as a marker for breast cancer.
Calaf GM; Echiburú-Chau C; Zhao YL; Hei TK
Int J Mol Med; 2008 May; 21(5):561-8. PubMed ID: 18425347
[TBL] [Abstract][Full Text] [Related]
35. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
[TBL] [Abstract][Full Text] [Related]
36. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.
Lewis JT; Ketterling RP; Halling KC; Reynolds C; Jenkins RB; Visscher DW
Am J Clin Pathol; 2005 Aug; 124(2):273-81. PubMed ID: 16040300
[TBL] [Abstract][Full Text] [Related]
37. Endothelin-1, Endothelin-A- and Endothelin-B-receptor expression in preinvasive and invasive breast disease.
Wülfing P; Diallo R; Kersting C; Wülfing C; Poremba C; Greb RR; Böcker W; Kiesel L
Oncol Rep; 2004 Apr; 11(4):791-6. PubMed ID: 15010874
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
Zheng WQ; Looi LM; Cheah PL
Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
[TBL] [Abstract][Full Text] [Related]
39. Metallothionein expression in invasive and in situ breast carcinomas.
Gallicchio LM; Flaws JA; Fowler BA; Ioffe OB
Cancer Detect Prev; 2005; 29(4):332-7. PubMed ID: 16122884
[TBL] [Abstract][Full Text] [Related]
40. Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.
Domagala W; Woźniak L; Lasota J; Weber K; Osborn M
Am J Pathol; 1990 Nov; 137(5):1059-64. PubMed ID: 2173410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
